# Reducing Complications in Pancreaticoduodenectomy

**Authors:** Josh B. Karpes, Ken Liu, Michael D. Crawford, Carlo Pulitano, Charbel Sandroussi, Jerome M. Laurence

PMC · DOI: 10.3390/cancers18040630 · 2026-02-14

## TL;DR

This paper reviews strategies to reduce complications in pancreatic surgery, focusing on technical, pharmacological, and systems-based approaches to improve patient outcomes.

## Contribution

The paper provides a comprehensive synthesis of current and emerging strategies to reduce complications in pancreaticoduodenectomy, emphasizing systems-based interventions and risk prediction.

## Key findings

- Complication severity and consequences can be reduced through improved prediction and systems of care.
- Centralisation and algorithm-driven postoperative surveillance show potential to improve survival.
- Modifiable factors like anastomotic reconstruction and nutritional optimization are key to reducing morbidity.

## Abstract

Pancreatic surgery is one of the most complex areas of abdominal surgery, with morbidity and mortality remaining a major challenge. Despite progress in surgical techniques and perioperative care, outcomes still vary widely, and there is no consensus on how to reliably prevent major complications. This study evaluates contemporary evidence on how complications develop, how they can be detected early, and the strategies that may reduce their frequency and impact. The evaluation includes technical factors during surgery, as well as non-technical factors outside of the operating theatre that may improve safety and outcomes. The goal of this review is to guide practice and future research to improve the safety of pancreatic resection in any environment.

Pancreatic surgery is a technically demanding field associated with frequent morbidity, with pancreatic fistula representing the dominant driver of major complications in pancreaticoduodenectomy (PD). Although refinements in operative technique, perioperative management, and institutional systems have contributed to incremental improvements, the overall incidence of clinically relevant complications has remained largely unchanged over recent decades. This narrative review provides a comprehensive overview of current strategies aimed at reducing morbidity and mortality after pancreaticoduodenectomy, focusing on modifiable technical, pharmacological, nutritional, and systems-based interventions, whilst acknowledging the underlying biological determinants that remain difficult to alter. This review synthesises contemporary evidence on fistula risk modelling, anastomotic reconstruction, and adjunctive operative techniques. The role of pharmacological interventions is examined alongside an evaluation of perioperative nutritional optimisation and enhanced recovery frameworks. Systems-based strategies such as centralisation, failure-to-rescue performance, protocolised pathways, and algorithm-driven postoperative surveillance are highlighted as emerging areas with substantial potential to impact survival independently of complication rates. Finally, this review explores future directions, including radiomics-based risk stratification, intraoperative imaging, and tailored postoperative care. Together, these domains provide a platform for reducing complication severity, standardising postoperative care, and ultimately improving patient outcomes. By integrating these perspectives, this review aims to present a comprehensive and in-depth narrative of how to reduce complications in pancreas surgery. Overall, this narrative review proposes that meaningful improvements in outcomes after PD likely do not arise from the elimination of complications altogether, but rather from improved prediction, prevention where possible, and critically, more effective systems of care that reduce the severity and consequences of complications when they occur.

## Full-text entities

- **Genes:** GAST (gastrin) [NCBI Gene 2520] {aka GAS}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SST (somatostatin) [NCBI Gene 6750] {aka SMST, SST1}
- **Diseases:** bleeding (MESH:D006470), organ dysfunction (MESH:D009102), pyloric dysfunction (MESH:D011707), gastroparesis (MESH:D018589), ischaemia (MESH:D007511), cholangitis (MESH:D002761), varices (MESH:D014648), abscess (MESH:D000038), inflammation (MESH:D007249), Complications (MESH:D008107), sarcopenia (MESH:D055948), injury to (MESH:D014947), Pancreas Surgery (MESH:D010190), pain (MESH:D010146), immune impairment (MESH:D020274), benign and malignant tumours (MESH:D009369), endocrine insufficiency (MESH:D000309), diabetes mellitus (MESH:D003920), pseudoaneurysm (MESH:D017541), blood loss (MESH:D016063), anorexia (MESH:D000855), postoperative nausea and vomiting (MESH:D020250), Delayed gastric emptying (MESH:D013272), muscle loss (MESH:D009135), postoperative morbidities (MESH:D019106), Fistula (MESH:D005402), fungal (MESH:D009181), pancreatic lesions (MESH:D010182), Infectious complications (MESH:D003141), intra-abdominal collections (MESH:D000082122), Pancreatic Fistula (MESH:D010185), thrombotic (MESH:D013927), Pancreatic exocrine insufficiency (MESH:D010188), ascites (MESH:D001201), tremor (MESH:D014202), Malnutrition (MESH:D044342), venous thromboembolism (MESH:D054556), micronutrient deficiency (MESH:D007153), death (MESH:D003643), malabsorption (MESH:D008286), hypertension (MESH:D006973), postoperative complication (MESH:D011183), infection (MESH:D007239), weight loss (MESH:D015431), leak (MESH:D019559)
- **Chemicals:** Octreotide (MESH:D015282), Hydrocortisone (MESH:D006854), steroids (MESH:D013256), LMWH (MESH:D006495), SA (-), Penicillin (MESH:D010406), Piperacillin-Tazobactam (MESH:D000077725), Cephalosporins (MESH:D002511), ICG (MESH:D007208)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939308/full.md

---
Source: https://tomesphere.com/paper/PMC12939308